MX343893B - Nuevos derivados de aril-quinolina. - Google Patents
Nuevos derivados de aril-quinolina.Info
- Publication number
- MX343893B MX343893B MX2014005373A MX2014005373A MX343893B MX 343893 B MX343893 B MX 343893B MX 2014005373 A MX2014005373 A MX 2014005373A MX 2014005373 A MX2014005373 A MX 2014005373A MX 343893 B MX343893 B MX 343893B
- Authority
- MX
- Mexico
- Prior art keywords
- quinoline derivatives
- new aryl
- compounds
- aryl
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La invención proporciona nuevos compuestos, que tienen la fórmula general (I) (ver Fórmula) en la que R1, R2, R3, R4, R5, R6 y n tienen los significados aquí definidos, composiciones que incluyen estos compuestos y métodos de utilización de estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11187967 | 2011-11-04 | ||
PCT/EP2012/071398 WO2013064465A1 (en) | 2011-11-04 | 2012-10-29 | New aryl-quinoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014005373A MX2014005373A (es) | 2014-07-30 |
MX343893B true MX343893B (es) | 2016-11-28 |
Family
ID=47115939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005373A MX343893B (es) | 2011-11-04 | 2012-10-29 | Nuevos derivados de aril-quinolina. |
Country Status (21)
Country | Link |
---|---|
US (2) | US9199938B2 (es) |
EP (1) | EP2773619B1 (es) |
JP (1) | JP6170060B2 (es) |
KR (1) | KR20140088194A (es) |
CN (1) | CN103906735B (es) |
AR (1) | AR088625A1 (es) |
AU (1) | AU2012331289B2 (es) |
BR (1) | BR112014010644A2 (es) |
CA (1) | CA2849945A1 (es) |
CL (1) | CL2014001060A1 (es) |
CO (1) | CO6930359A2 (es) |
CR (1) | CR20140135A (es) |
EA (1) | EA201490846A1 (es) |
ES (1) | ES2609773T3 (es) |
IL (1) | IL231950B (es) |
MX (1) | MX343893B (es) |
MY (1) | MY169267A (es) |
PE (1) | PE20142282A1 (es) |
SG (1) | SG11201401937YA (es) |
TW (1) | TWI616437B (es) |
WO (1) | WO2013064465A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20142282A1 (es) | 2011-11-04 | 2015-01-08 | Hoffmann La Roche | Nuevos derivados de aril-quinolina |
CA2873295A1 (en) * | 2012-08-24 | 2014-02-27 | F. Hoffmann-La Roche Ag | New bicyclicpyridine derivatives |
CN105294648B (zh) * | 2015-11-30 | 2017-11-28 | 山东罗欣药业集团股份有限公司 | 一种西他沙星的制备方法 |
WO2017184547A1 (en) | 2016-04-18 | 2017-10-26 | New York University | Quinoline compounds as modulators of rage activity and uses thereof |
EP3246028A1 (en) * | 2016-05-18 | 2017-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline compounds for increasing insuline release |
JP7139323B2 (ja) | 2016-11-01 | 2022-09-20 | エフ.ホフマン-ラ ロシュ アーゲー | Cns関連疾患を処置するための1,3-ジヒドロ-1,4-ベンゾジアゼピン-2-チオン |
WO2018165120A1 (en) * | 2017-03-06 | 2018-09-13 | Gemphire Therapeutics Inc. | Effect of carboxyalkylethers on obesity symptoms and lipodystropy |
CN107311847B (zh) * | 2017-07-12 | 2020-11-10 | 安徽省诚联医药科技有限公司 | 5-溴-2-氯-4′-乙氧基二苯甲烷的制备方法 |
CN109280028B (zh) * | 2017-07-19 | 2022-03-25 | 上海医药工业研究院 | 喹啉类化合物及其在dpp-4酶抑制剂的应用 |
JP7403472B2 (ja) | 2018-05-09 | 2023-12-22 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規キノリン誘導体 |
US20200354374A1 (en) * | 2019-05-06 | 2020-11-12 | Inspira, LLC | Chemical Entities, Pharmaceutical Formulations, and Methods for Treating Fibrosis |
CN113277978B (zh) * | 2021-06-02 | 2022-06-03 | 河南师范大学 | 一种2,4-双取代喹啉类化合物的制备方法 |
CN116693456A (zh) * | 2022-02-28 | 2023-09-05 | 复旦大学 | 异喹啉酮类化合物及其制备方法和应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
TW205037B (es) * | 1989-10-06 | 1993-05-01 | Takeda Pharm Industry Co Ltd | |
US5371227A (en) | 1991-10-28 | 1994-12-06 | Synthelabo | Quinoline derivatives, process for their preparation, and their therapeutic applications |
NO179904C (no) * | 1992-09-04 | 1997-01-08 | Takeda Chemical Industries Ltd | Kondenserte heterocykliske forbindelser og deres anvendelse |
JP3724818B2 (ja) * | 1992-09-04 | 2005-12-07 | 武田薬品工業株式会社 | 縮合複素環化合物、その製造法および剤 |
JPH0769890A (ja) * | 1993-06-29 | 1995-03-14 | Takeda Chem Ind Ltd | キノリンまたはキナゾリン誘導体を含んでなる医薬組成物 |
JPH08225531A (ja) * | 1994-03-08 | 1996-09-03 | Takeda Chem Ind Ltd | キノリンまたはキナゾリン誘導体を含んでなる医薬およびそれに用いる新規誘導体 |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6900226B2 (en) | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
WO2004018461A2 (en) * | 2002-08-23 | 2004-03-04 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
KR101154431B1 (ko) * | 2002-11-29 | 2012-06-15 | 주식회사 씨앤드씨신약연구소 | 치환된 1h-피리딘-2-온 유도체 |
WO2004063156A1 (en) * | 2003-01-08 | 2004-07-29 | Biovitrum Ab | Novel indole derivates as fabp-4 inhibitors |
CA2533626A1 (en) * | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
AU2008303602A1 (en) | 2007-09-27 | 2009-04-02 | F. Hoffmann-La Roche Ag | Quinoline derivatives as 5HT5A receptor antagonists |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
GB0818365D0 (en) | 2008-10-07 | 2008-11-12 | Argenta Discovery Ltd | Quinoline compounds |
EP2358716B1 (en) * | 2008-11-12 | 2016-01-06 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (fabp) |
US20100125091A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
PE20142282A1 (es) | 2011-11-04 | 2015-01-08 | Hoffmann La Roche | Nuevos derivados de aril-quinolina |
MX2014005296A (es) | 2011-11-04 | 2014-08-27 | Afraxis Holdings Inc | Inhibidores de pak para el tratamiento del sindrome del x fragil. |
US9497965B2 (en) | 2011-11-04 | 2016-11-22 | Syngenta Participations Ag | Pesticidal compounds |
-
2012
- 2012-10-29 PE PE2014000640A patent/PE20142282A1/es not_active Application Discontinuation
- 2012-10-29 CA CA2849945A patent/CA2849945A1/en not_active Abandoned
- 2012-10-29 WO PCT/EP2012/071398 patent/WO2013064465A1/en active Application Filing
- 2012-10-29 SG SG11201401937YA patent/SG11201401937YA/en unknown
- 2012-10-29 EA EA201490846A patent/EA201490846A1/ru unknown
- 2012-10-29 BR BR112014010644A patent/BR112014010644A2/pt not_active IP Right Cessation
- 2012-10-29 EP EP12780486.2A patent/EP2773619B1/en not_active Not-in-force
- 2012-10-29 KR KR1020147014643A patent/KR20140088194A/ko not_active Application Discontinuation
- 2012-10-29 MX MX2014005373A patent/MX343893B/es active IP Right Grant
- 2012-10-29 ES ES12780486.2T patent/ES2609773T3/es active Active
- 2012-10-29 MY MYPI2014701086A patent/MY169267A/en unknown
- 2012-10-29 JP JP2014539306A patent/JP6170060B2/ja not_active Expired - Fee Related
- 2012-10-29 AU AU2012331289A patent/AU2012331289B2/en not_active Ceased
- 2012-10-29 CN CN201280053295.8A patent/CN103906735B/zh not_active Expired - Fee Related
- 2012-10-31 TW TW101140406A patent/TWI616437B/zh not_active IP Right Cessation
- 2012-11-01 US US13/666,202 patent/US9199938B2/en not_active Expired - Fee Related
- 2012-11-02 AR ARP120104109A patent/AR088625A1/es unknown
-
2014
- 2014-03-24 CR CR20140135A patent/CR20140135A/es unknown
- 2014-03-31 CO CO14068491A patent/CO6930359A2/es unknown
- 2014-04-03 IL IL231950A patent/IL231950B/en not_active IP Right Cessation
- 2014-04-25 CL CL2014001060A patent/CL2014001060A1/es unknown
-
2015
- 2015-11-11 US US14/938,005 patent/US9809599B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CO6930359A2 (es) | 2014-04-28 |
US20160060270A1 (en) | 2016-03-03 |
CN103906735B (zh) | 2016-12-07 |
CR20140135A (es) | 2014-06-19 |
MX2014005373A (es) | 2014-07-30 |
CA2849945A1 (en) | 2013-05-10 |
TW201326130A (zh) | 2013-07-01 |
NZ720278A (en) | 2017-08-25 |
AU2012331289A1 (en) | 2014-04-10 |
JP6170060B2 (ja) | 2017-07-26 |
BR112014010644A2 (pt) | 2017-04-25 |
NZ622717A (en) | 2016-06-24 |
EP2773619A1 (en) | 2014-09-10 |
AU2012331289B2 (en) | 2017-07-13 |
EA201490846A1 (ru) | 2014-07-30 |
TWI616437B (zh) | 2018-03-01 |
US9809599B2 (en) | 2017-11-07 |
US9199938B2 (en) | 2015-12-01 |
CL2014001060A1 (es) | 2014-11-07 |
US20130116234A1 (en) | 2013-05-09 |
EP2773619B1 (en) | 2016-11-16 |
CN103906735A (zh) | 2014-07-02 |
KR20140088194A (ko) | 2014-07-09 |
IL231950B (en) | 2018-02-28 |
MY169267A (en) | 2019-03-20 |
SG11201401937YA (en) | 2014-05-29 |
JP2014532681A (ja) | 2014-12-08 |
PE20142282A1 (es) | 2015-01-08 |
ES2609773T3 (es) | 2017-04-24 |
WO2013064465A1 (en) | 2013-05-10 |
AR088625A1 (es) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501179B1 (en) | New bicyclic dihydroisoquinoline-1-one derivatives | |
PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
PH12015500263A1 (en) | New bicyclic derivatives | |
MY169043A (en) | New dihydroquinoline-2-one derivatives | |
MY169267A (en) | New aryl-quinoline derivatives | |
MY186165A (en) | New bicyclic dihydroquinoline-2-one derivatives | |
MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
PH12016500643A1 (en) | New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
MX343225B (es) | Nuevos derivados de aril-benzocicloalquil-amida. | |
MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
MX2012008141A (es) | Compuestos y metodos. | |
MX2015007097A (es) | Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer. | |
MX2015013365A (es) | Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag). | |
MX2013005753A (es) | Nuevos derivados de biaril amida. | |
MX342311B (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
MX346980B (es) | Nuevos compuestos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona y octahidropiridinona. | |
MX2015011005A (es) | Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa. | |
GB2511240A (en) | Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof | |
MX344429B (es) | Nuevos compuestos de hexahidropirroloimidazolona. | |
MX2014008856A (es) | Derivados de imidazolilcetona como inhibidores de aldosterona sintasa. | |
MX2016002762A (es) | Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa. | |
MX2015009377A (es) | Compuestos radiomarcados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |